冻融胚胎移植 中国就医指南

Frozen-thawed embryo transfer (FET) is not a disease but a core assisted reproductive technology (ART) procedure used in reproductive medicine to achieve pregnancy following in vitro fertilization (IVF). In FET, previously cryopreserved embryos—typically vitrified at the blastocyst stage—are carefully thawed and transferred into a prepared endometrial cavity during a natural or hormonally controlled cycle. Unlike fresh embryo transfer, FET decouples ovarian stimulation and embryo transfer, allowing for optimal endometrial receptivity assessment, avoidance of ovarian hyperstimulation syndrome (OHSS) risks, and improved synchronization between embryo developmental stage and uterine environment. Pathophysiologically, FET success hinges on three interdependent factors: embryo viability post-thaw (influenced by cryopreservation technique, embryo quality, and laboratory expertise), endometrial receptivity (modulated by hormonal priming, immune tolerance, and molecular biomarkers such as integrins and HOXA10), and procedural precision (including catheter placement, uterine contractility management, and minimization of trauma). Epidemiologically, FET accounts for over 60% of all IVF cycles in high-volume fertility centers across China and North America, with cumulative live birth rates per initiated FET cycle ranging from 45–60% in women under 35, declining to 25–35% in those aged 40–42. Key risk factors affecting outcomes include maternal age (>37 years), diminished ovarian reserve (AMH <1.1 ng/mL), recurrent implantation failure (≥3 prior failed transfers), endometriosis-associated inflammation, chronic endometritis, suboptimal endometrial thickness (<7 mm), and subclinical thyroid dysfunction. While FET itself is minimally invasive and carries low procedural morbidity, the broader fertility journey imposes substantial psychosocial burden: patients frequently report elevated anxiety, depression, marital strain, financial stress, and occupational disruption. The cyclical nature of monitoring, hormone injections, and repeated negative pregnancy tests contributes to emotional exhaustion and reduced health-related quality of life (HRQoL), particularly when multiple FET attempts are required. Importantly, FET offers distinct advantages over fresh transfer—including higher implantation and live birth rates in certain populations (e.g., PCOS, high responders), lower preterm birth and low birth weight incidence, and greater flexibility in timing—making it a first-line strategy in modern ART protocols. However, its efficacy remains highly dependent on integrated clinical, embryological, and endometrial diagnostics, underscoring the need for individualized, multidisciplinary care in reproductive medicine departments.

# 冻融胚胎移植（FET）治疗方案与费用明细（生殖医学科）

一、非手术/药物/监测方案

适用人群：内膜厚度≥7mm、激素水平达标、无宫腔粘连或免疫异常者。

• •自然周期FET：仅需超声监测排卵+黄体支持（地屈孕酮/黄体酮注射），总费用 3,800–5,200元（含B超监测4次、血雌孕激素6次、药物费）。
• •激素替代周期（HRT）FET：雌二醇片+黄体酮凝胶/肌注，全程内膜准备+转化，总费用 6,500–9,800元（含雌激素监测3次、孕酮转化期B超2次、血激素5次、药物费）。

二、手术/核心介入方案

适用人群：宫腔镜证实轻中度粘连、息肉或内膜炎需同步处理者。

• •宫腔镜下内膜修整术+FET同期移植：术前宫腔镜检查+活检+机械性内膜刺激，术后当月启动HRT周期，全套费用 12,600–16,800元（含宫腔镜手术费4,200元、麻醉费1,500元、病理检查800元、FET周期费用6,500–9,800元、术前感染四项及心电图等检查费1,600元）。

三、特殊复杂方案

适用人群：反复种植失败（≥3次）、薄型内膜（<6mm）、免疫紊乱或血栓倾向者。

• •个体化联合干预FET：G-CSF宫腔灌注+低分子肝素+泼尼松+粒细胞集落刺激因子，总费用 22,000–35,000元（含免疫指标检测3,200元、G-CSF药物00元、抗凝及激素管理费4,800元、升级内膜监测与胚胎培养附加费5,500元）。

四、方案快速选择指南

• •预算有限/首次尝试：优选自然4,500元）；
• •内膜反应差/工作繁忙：选HRT周期（约8,000元），时间可控；
• •2次以上失败/疑难病例：启动宫腔镜+FET或个体化方案（≥22,000元），需生殖免疫专科评估。